Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Coherus Oncology (CHRS) Net Income (2016 - 2025)

Coherus Oncology's Net Income history spans 13 years, with the latest figure at $8.7 million for Q4 2025.

  • For Q4 2025, Net Income rose 289.09% year-over-year to $8.7 million; the TTM value through Dec 2025 reached $351.1 million, up 43.97%, while the annual FY2025 figure was $351.1 million, 43.97% up from the prior year.
  • Net Income for Q4 2025 was $8.7 million at Coherus Oncology, down from $9.0 million in the prior quarter.
  • Across five years, Net Income topped out at $342.6 million in Q2 2025 and bottomed at -$172.9 million in Q1 2021.
  • The 5-year median for Net Income is -$39.1 million (2021), against an average of -$11.1 million.
  • The largest annual shift saw Net Income tumbled 586.19% in 2021 before it surged 717.15% in 2025.
  • A 5-year view of Net Income shows it stood at -$45.7 million in 2021, then dropped by 28.87% to -$58.9 million in 2022, then tumbled by 35.3% to -$79.7 million in 2023, then surged by 94.22% to -$4.6 million in 2024, then surged by 289.09% to $8.7 million in 2025.
  • Per Business Quant, the three most recent readings for CHRS's Net Income are $8.7 million (Q4 2025), $9.0 million (Q3 2025), and $342.6 million (Q2 2025).